This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignee: Shionogi Company Limited. Active years: 2020-2021.
Company Filing History:
Years Active: 2020-2021
Title: Hiroaki Aino: Innovator in Monoclonal Antibody Development
Introduction
Hiroaki Aino is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of humanized monoclonal antibodies. With a total of 2 patents to his name, Aino's work focuses on addressing critical health issues related to vascular endothelial lipase.
Latest Patents
Aino's latest patents include a method for the treatment or prevention of diseases associated with vascular endothelial lipase. This involves administering a humanized monoclonal antibody that selectively inhibits the enzymatic activity of vascular endothelial lipase. The pharmaceutical compositions containing this antibody are particularly useful for treating arteriosclerosis or metabolic syndrome. Another patent also centers on a humanized monoclonal antibody that inhibits the enzymatic activity of vascular endothelial lipase, reinforcing the potential therapeutic applications in managing these health conditions.
Career Highlights
Hiroaki Aino is currently associated with Shionogi Company Limited, where he continues to innovate in the field of pharmaceuticals. His work has been instrumental in advancing treatments that target vascular-related diseases, showcasing his commitment to improving patient outcomes.
Collaborations
Aino collaborates with esteemed colleagues such as Sunao Imai and Shoichi Naito. Their combined expertise contributes to the ongoing research and development efforts at Shionogi Company Limited.
Conclusion
Hiroaki Aino's contributions to the field of monoclonal antibodies highlight his role as a key innovator in biotechnology. His patents reflect a dedication to addressing significant health challenges, particularly those related to vascular health.